Please login to the form below

Not currently logged in
Email:
Password:

cholera

This page shows the latest cholera news and features for those working in and with pharma, biotech and healthcare.

Givlaari, Rybelsus lead crowded CHMP recommendations

Givlaari, Rybelsus lead crowded CHMP recommendations

The CHMP also recommended PaxVax’s cholera vaccine Vaxchora for prophylaxis against choleam and Eli Lilly’s new fast-acting mealtime insulin Liumjev, to improve glycemic control in diabetes in adults.

Latest news

  • The power of pharma businesses to drive social change The power of pharma businesses to drive social change

    Our research teams are collaborating with peers from organisations around the world to help in the development of effective treatments for diseases such as Chagas, cholera, dengue fever and schistosomiasis.

  • FDA approves first cholera vaccine in US FDA approves first cholera vaccine in US

    The approval also comes against the backdrop of a worldwide shortage in oral cholera vaccines, which include Valneva's Dukoral and the International Vaccine Institute's Shanchol. ... It is a live attenuated vaccine, incorporating a weakened strain of the

  • Sanofi enters vaccines partnership with Sutro Sanofi enters vaccines partnership with Sutro

    Sanofi Pasteur's vaccines currently cover 20 infectious diseases, including tuberculosis, cholera, influenza and hepatitis, and it is currently investigating a product to protect against the dengue virus.

  • J&J to buy remaining shares in Crucell

    as hepatitis, influenza, typhoid and cholera.

  • Kicking the habit

    Preliminary data from a phase I trial of the vaccine, which comprises a nicotine derivative conjugated to a recombinant cholera toxin B, indicated that self-reported quit rates were considerably greater

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Dimitri Azzopardi
Case-study for thalassaemia: Dimitri Azzopardi
An in-depth look at beta thalassaemia for Rare Disease Day...
Delivering change through better rare disease communications
OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes....
Interim analysis clinical trials
Assessing the value of interim analyses in clinical trials
Why its important and when its needed...

Infographics